Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases

J. Eric Ahlskog, Ryan J. Uitti, Gertrude M. Tyce, John F. O'Brien, Ronald Carl Petersen, Emre Kokmen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Prior studies have documented functional and pathological compromise of the peripheral sympathetic nervous system in patients with Parkinson's disease, suggesting the possibility of reduced catecholamine release into the circulation. We measured free plasma catechols in early and untreated patients with Parkinson's disease, but found no evidence of reduced concentrations, compared to control subjects or a group of patients with probable Alzheimer's disease. Rather, there was a significant elevation of plasma norepinephrine within the Parkinson's disease group. Furthermore, 6 of 15 untreated Parkinson's disease patients (40%) displayed markedly elevated plasma concentrations of the catecholamine MAO metabolites, DOPAC or DOPEG. Despite this finding, platelet MAO-B activity measured in these and all other Parkinson's disease patients fell well within the range of the control subjects, and was also statistically similar to the group with Alzheimer's type dementia, Plasma dopa levels were similar in all groups, whereas the majority of patients in the three groups had plasma free dopamine and epinephrine concentrations below the limits of detection. These trends toward increased, rather than decreased, circulating catechol concentrations suggest that peripheral sympathetic nervous system catecholamine production and release is not severely compromised in patients with early Parkinson's disease. In addition, we were unable to confirm certain previous reports of elevated MAO-B activity inpatients with Parkinson's or Alzheimer's diseases.

Original languageEnglish (US)
Pages (from-to)162-168
Number of pages7
JournalJournal of the Neurological Sciences
Volume136
Issue number1-2
DOIs
StatePublished - 1996

Fingerprint

Catechol Oxidase
Monoamine Oxidase
Parkinson Disease
Alzheimer Disease
Catecholamines
Sympathetic Nervous System
Peripheral Nervous System
Catechols
3,4-Dihydroxyphenylacetic Acid
Dihydroxyphenylalanine
Epinephrine
Limit of Detection
Inpatients
Dopamine
Norepinephrine
Blood Platelets

Keywords

  • Alzheimer's disease
  • Catecholamine
  • DOPAC
  • DOPEG
  • Monoamine oxidase
  • Parkinson's disease

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases. / Ahlskog, J. Eric; Uitti, Ryan J.; Tyce, Gertrude M.; O'Brien, John F.; Petersen, Ronald Carl; Kokmen, Emre.

In: Journal of the Neurological Sciences, Vol. 136, No. 1-2, 1996, p. 162-168.

Research output: Contribution to journalArticle

Ahlskog, J. Eric ; Uitti, Ryan J. ; Tyce, Gertrude M. ; O'Brien, John F. ; Petersen, Ronald Carl ; Kokmen, Emre. / Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases. In: Journal of the Neurological Sciences. 1996 ; Vol. 136, No. 1-2. pp. 162-168.
@article{44ff9bfe24f241eda9ce29115ccc7492,
title = "Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases",
abstract = "Prior studies have documented functional and pathological compromise of the peripheral sympathetic nervous system in patients with Parkinson's disease, suggesting the possibility of reduced catecholamine release into the circulation. We measured free plasma catechols in early and untreated patients with Parkinson's disease, but found no evidence of reduced concentrations, compared to control subjects or a group of patients with probable Alzheimer's disease. Rather, there was a significant elevation of plasma norepinephrine within the Parkinson's disease group. Furthermore, 6 of 15 untreated Parkinson's disease patients (40{\%}) displayed markedly elevated plasma concentrations of the catecholamine MAO metabolites, DOPAC or DOPEG. Despite this finding, platelet MAO-B activity measured in these and all other Parkinson's disease patients fell well within the range of the control subjects, and was also statistically similar to the group with Alzheimer's type dementia, Plasma dopa levels were similar in all groups, whereas the majority of patients in the three groups had plasma free dopamine and epinephrine concentrations below the limits of detection. These trends toward increased, rather than decreased, circulating catechol concentrations suggest that peripheral sympathetic nervous system catecholamine production and release is not severely compromised in patients with early Parkinson's disease. In addition, we were unable to confirm certain previous reports of elevated MAO-B activity inpatients with Parkinson's or Alzheimer's diseases.",
keywords = "Alzheimer's disease, Catecholamine, DOPAC, DOPEG, Monoamine oxidase, Parkinson's disease",
author = "Ahlskog, {J. Eric} and Uitti, {Ryan J.} and Tyce, {Gertrude M.} and O'Brien, {John F.} and Petersen, {Ronald Carl} and Emre Kokmen",
year = "1996",
doi = "10.1016/0022-510X(95)00318-V",
language = "English (US)",
volume = "136",
pages = "162--168",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases

AU - Ahlskog, J. Eric

AU - Uitti, Ryan J.

AU - Tyce, Gertrude M.

AU - O'Brien, John F.

AU - Petersen, Ronald Carl

AU - Kokmen, Emre

PY - 1996

Y1 - 1996

N2 - Prior studies have documented functional and pathological compromise of the peripheral sympathetic nervous system in patients with Parkinson's disease, suggesting the possibility of reduced catecholamine release into the circulation. We measured free plasma catechols in early and untreated patients with Parkinson's disease, but found no evidence of reduced concentrations, compared to control subjects or a group of patients with probable Alzheimer's disease. Rather, there was a significant elevation of plasma norepinephrine within the Parkinson's disease group. Furthermore, 6 of 15 untreated Parkinson's disease patients (40%) displayed markedly elevated plasma concentrations of the catecholamine MAO metabolites, DOPAC or DOPEG. Despite this finding, platelet MAO-B activity measured in these and all other Parkinson's disease patients fell well within the range of the control subjects, and was also statistically similar to the group with Alzheimer's type dementia, Plasma dopa levels were similar in all groups, whereas the majority of patients in the three groups had plasma free dopamine and epinephrine concentrations below the limits of detection. These trends toward increased, rather than decreased, circulating catechol concentrations suggest that peripheral sympathetic nervous system catecholamine production and release is not severely compromised in patients with early Parkinson's disease. In addition, we were unable to confirm certain previous reports of elevated MAO-B activity inpatients with Parkinson's or Alzheimer's diseases.

AB - Prior studies have documented functional and pathological compromise of the peripheral sympathetic nervous system in patients with Parkinson's disease, suggesting the possibility of reduced catecholamine release into the circulation. We measured free plasma catechols in early and untreated patients with Parkinson's disease, but found no evidence of reduced concentrations, compared to control subjects or a group of patients with probable Alzheimer's disease. Rather, there was a significant elevation of plasma norepinephrine within the Parkinson's disease group. Furthermore, 6 of 15 untreated Parkinson's disease patients (40%) displayed markedly elevated plasma concentrations of the catecholamine MAO metabolites, DOPAC or DOPEG. Despite this finding, platelet MAO-B activity measured in these and all other Parkinson's disease patients fell well within the range of the control subjects, and was also statistically similar to the group with Alzheimer's type dementia, Plasma dopa levels were similar in all groups, whereas the majority of patients in the three groups had plasma free dopamine and epinephrine concentrations below the limits of detection. These trends toward increased, rather than decreased, circulating catechol concentrations suggest that peripheral sympathetic nervous system catecholamine production and release is not severely compromised in patients with early Parkinson's disease. In addition, we were unable to confirm certain previous reports of elevated MAO-B activity inpatients with Parkinson's or Alzheimer's diseases.

KW - Alzheimer's disease

KW - Catecholamine

KW - DOPAC

KW - DOPEG

KW - Monoamine oxidase

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0029990149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029990149&partnerID=8YFLogxK

U2 - 10.1016/0022-510X(95)00318-V

DO - 10.1016/0022-510X(95)00318-V

M3 - Article

VL - 136

SP - 162

EP - 168

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -